Teradyne Reports Second Quarter 2022 Results

® is a registered trademark of Teradyne, Inc. in the U.S. and other countries.

Safe Harbor Statement
This release contains forward-looking statements regarding Teradyne’s future business prospects, the impact of the global pandemic of the novel strain of the coronavirus (COVID-19), results of operations, market conditions, earnings per share, the impact of supply chain conditions on the business, customer sales expectations, the payment of a quarterly dividend, the repurchase of Teradyne common stock pursuant to a share repurchase program, sanctions against Russia and Russian companies, and the impact of U.S. and Chinese export and tariff laws. Such statements are based on the current assumptions and expectations of Teradyne’s management and are neither promises nor guarantees of future performance, events, customer sales, supply chain conditions or improvements, earnings per share, use of cash, payment of dividends, repurchases of common stock, payment of the senior convertible notes, the impact of the COVID-19 pandemic, sanctions against Russia and Russian companies, the impact of any tariffs or export controls imposed in the U.S. or China; compliance with trade protection measures or export restrictions; the impact of U.S. Department of Commerce or other government agency regulations relating to Huawei, HiSilicon and other customers or potential customers; or the impact of U.S. Department Commerce export control regulations for certain U.S. products and technology sold to military end users or for military end-use in China, Russia and Venezuela. There can be no assurance that management’s estimates of Teradyne’s future results or other forward-looking statements will be achieved. Specifically, Teradyne’s 2024 earnings model is aspirational and includes many assumptions. There can be no assurance that these assumptions will be accurate or that model results will be achieved. As set forth below, there are many factors that could cause our 2024 earnings model and actual results to differ materially from those presently expected. Additionally, the current dividend and share repurchase programs may be modified, suspended or discontinued at any time.

Following Russia’s invasion of Ukraine in February 2022, the U.S. and other countries imposed significant sanctions against the Russian government and many Russian companies and individuals. Although Teradyne does not have significant operations in Russia, the sanctions could impact Teradyne’s business in other countries and could have a negative impact on the Company’s supply chain, either of which could adversely affect Teradyne’s business and financial results.

COVID-19 has resulted in authorities implementing numerous measures to try to contain the virus, such as travel bans and restrictions, quarantines, government vaccination mandates and other government regulations. These measures have impacted and may further impact Teradyne’s workforce and operations, the operations of its customers, and those of its contract manufacturers and suppliers. As Teradyne implements measures to comply with additional regulations, the Company may experience increased compliance costs, increased risk of non-compliance and increased risk of employee attrition.

The COVID-19 pandemic has adversely impacted the Company’s results of operations, including increased costs company-wide and constraints within the Company’s supply chain. The Company cannot accurately estimate the amount of the impact on Teradyne’s 2022 financial results and to its future financial results. The COVID-19 outbreak has significantly increased economic and demand uncertainty in Teradyne’s markets. This uncertainty resulted in a significant decrease in demand for certain Teradyne products and could continue to impact demand for an uncertain period of time. The spread of COVID-19 has caused Teradyne to modify its business practices (including employee travel, employees working remotely, and cancellation of in person participation in meetings, events and conferences) and the Company may take further actions as may be required by government authorities or that it determines are in the best interests of its employees, customers, contract manufacturers and suppliers. There is uncertainty that such measures will be sufficient to mitigate the risks posed by the virus, and Teradyne’s ability to perform critical functions could be impacted. The degree to which COVID-19 continues to impact Teradyne’s results will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and continued spread of the virus, its severity, the actions to contain the virus or the availability and impact of vaccines in countries where the Company does business, and how quickly and to what extent normal economic and operating conditions can resume.

Important factors that could cause actual results, the 2024 earnings model, earnings per share, use of cash, dividend payments, repurchases of common stock, or payment of the senior convertible notes to differ materially from those presently expected include: conditions affecting the markets in which Teradyne operates; decreased or delayed product demand from one or more significant customers; development, delivery and acceptance of new products; the ability to grow the Industrial Automation business; increased research and development spending; deterioration of Teradyne’s financial condition; the continued impact of the COVID-19 pandemic and related government responses on the market and demand for Teradyne’s products, on its contract manufacturers and supply chain, and on its workforce; the impact of the global semiconductor supply shortage on our supply chain and contract manufacturers; the consummation and success of any mergers or acquisitions; demand for products by the Company’s largest customers; unexpected cash needs; insufficient cash flow to make required payments and pay the principal amount on the senior convertible notes; the business judgment of the board of directors that a declaration of a dividend or the repurchase of common stock is not in the Company’s best interests; additional U.S. tax regulations or IRS guidance; the impact of any tariffs or export controls imposed in the U.S. or China; compliance with trade protection measures or export restrictions; the impact of U.S. Department of Commerce or other government agency regulations relating to Huawei, HiSilicon and other customers or potential customers; the impact of U.S. Department Commerce export control regulations for certain U.S. products and technology sold to military end users or for military end-use in China, Russia and Venezuela; sanctions imposed against the Russian government and certain Russian companies and individuals by the U.S., and other countries; and other events, factors and risks disclosed in filings with the SEC, including, but not limited to, the “Risk Factors” sections of Teradyne’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and Quarterly Report on Form 10-Q for the fiscal quarter ended April, 3, 2022. The forward-looking statements provided by Teradyne in this press release represent management’s views as of the date of this release. Teradyne anticipates that subsequent events and developments may cause management’s views to change. However, while Teradyne may elect to update these forward-looking statements at some point in the future, Teradyne specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Teradyne’s views as of any date subsequent to the date of this release.


TERADYNE, INC. REPORT FOR SECOND FISCAL QUARTER OF 2022          
                 
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS      
       
                           
          Quarter Ended   Six Months Ended
          July 3,
2022
  April 3,
2022
  July 4,
2021
  July 3,
2022
  July 4,
2021
                           
Net revenues   $ 840,766     $ 755,370     $ 1,085,728     $ 1,596,136     $ 1,867,334  
  Cost of revenues (exclusive of acquired intangible assets amortization shown separately below) (1)     334,377       300,437       438,739       634,814       758,727  
                           
Gross profit     506,389       454,933       646,989       961,322       1,108,607  
                           
Operating expenses:                    
  Selling and administrative     139,533       140,185       140,187       279,718       269,984  
  Engineering and development     111,951       108,116       110,021       220,067       210,423  
  Acquired intangible assets amortization     4,871       5,063       5,402       9,934       10,938  
  Restructuring and other (2)     2,044       15,714       2,507       17,758       (4,623 )
      Operating expenses     258,399       269,078       258,117       527,477       486,722  
                           
Income from operations     247,990       185,855       388,872       433,845       621,885  
                           
  Interest and other expense (3)     9,398       5,496       4,846       14,894       13,866  
                           
Income before income taxes     238,592       180,359       384,026       418,951       608,019  
  Income tax provision     40,805       18,431       55,707       59,236       74,188  
Net income   $ 197,787     $ 161,928     $ 328,319     $ 359,715     $ 533,831  
                           
Net income per common share:                    
Basic   $ 1.24     $ 1.00     $ 1.98     $ 2.24     $ 3.21  
Diluted   $ 1.16     $ 0.92     $ 1.76     $ 2.07     $ 2.85  
                           
Weighted average common shares - basic     159,563       162,048       165,995       160,805       166,243  
                           
Weighted average common shares - diluted (4)     171,159       175,575       186,750       173,367       187,245  
                           
                           
Cash dividend declared per common share   $ 0.11     $ 0.11     $ 0.10     $ 0.22     $ 0.20  
                           
                           
                           
(1 ) Cost of revenues includes:   Quarter Ended   Six Months Ended
          July 3,
2022
  April 3,
2022
  July 4,
2021
  July 3,
2022
  July 4,
2021
      Provision for excess and obsolete inventory   $ 5,105     $ 1,590     $ 798     $ 6,695     $ 3,625  
      Sale of previously written down inventory     (449 )     (262 )     (428 )     (711 )     (1,218 )
          $ 4,656     $ 1,328     $ 370     $ 5,984     $ 2,407  
                           
(2 ) Restructuring and other consists of:   Quarter Ended   Six Months Ended
          July 3,
2022
  April 3,
2022
  July 4,
2021
  July 3,
2022
  July 4,
2021
      Employee severance   $ 383     $ 551     $ 436     $ 934     $ 624  
      Litigation settlement     -       14,700       -       14,700       -  
      Acquisition related expenses and compensation     -       (201 )     275       (201 )     38  
      Contingent consideration fair value adjustment     -       -       -       -       (7,227 )
      Other     1,661       664       1,796       2,325       1,942  
          $ 2,044     $ 15,714     $ 2,507     $ 17,758     $ (4,623 )
                           
(3 ) Interest and other includes:   Quarter Ended   Six Months Ended
          July 3,
2022
  April 3,
2022
  July 4,
2021
  July 3,
2022
  July 4,
2021
      Non-cash convertible debt interest   $ -     $ -     $ 3,277     $ -     $ 6,858  
      Loss on convertible debt conversions     -       -       1,175       -       5,244  
      Pension actuarial gains     -       -       (627 )     -       (627 )
          $ -     $ -     $ 3,825     $ -     $ 11,475  
                           
(4 ) Under GAAP, when calculating diluted earnings per share, convertible debt must be assumed to have converted if the effect on EPS would be dilutive. Diluted shares assume the conversion of the convertible debt as the effect would be dilutive. Accordingly, for the quarters ended July 3, 2022, April 3, 2022 and July 4, 2021, 1.9 million, 2.5 million and 9.6 million shares, respectively, have been included in diluted shares. For the six months ended July 3, 2022 and July 4, 2021, 2.2 million and 9.9 million shares, respectively, have been included in diluted shares. For the quarters ended July 3, 2022, April 3, 2022 and July 4, 2021, diluted shares also included 9.0 million, 10.0 million and 10.1 million shares, respectively, from the convertible note hedge transaction. For the six months ended July 3, 2022 and July 4, 2021, diluted shares included 9.5 million and 9.8 million shares, respectively, from the convertible note hedge transaction.
     
CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands)                    
                           
          July 3,
2022
  December 31,
2021
           
Assets                        
  Cash and cash equivalents   $ 572,023     $ 1,122,199              
  Marketable securities     209,846       244,231              
  Accounts receivable, net     683,739       550,749              
  Inventories, net     295,625       243,330              
  Prepayments     498,093       406,266              
  Other current assets     11,109       9,452              
      Total current assets     2,270,435       2,576,227              
                           
  Property, plant and equipment, net     411,263       387,240              
  Operating lease right-of-use assets, net     71,812       68,807              
  Marketable securities     111,999       133,858              
  Deferred tax assets     126,639       102,428              
  Retirement plans assets     14,245       15,110              
  Other assets     26,942       24,096              
  Acquired intangible assets, net     62,509       75,635              
  Goodwill     397,733       426,024              
      Total assets   $ 3,493,577     $ 3,809,425              
                           
Liabilities                      
  Accounts payable   $ 175,606     $ 153,133              
  Accrued employees' compensation and withholdings     190,506       253,667              
  Deferred revenue and customer advances     163,127       146,185              
  Other accrued liabilities     133,881       124,187              
  Operating lease liabilities     17,770       19,977              
  Income taxes payable     106,863       88,789              
  Current debt     9,632       19,182              
      Total current liabilities     797,385       805,120              
                           
  Retirement plans liabilities     141,884       151,141              
  Long-term deferred revenue and customer advances     50,357       54,921              
  Long-term other accrued liabilities     15,530       15,497              
  Deferred tax liabilities     3,143       6,327              
  Long-term operating lease liabilities     62,751       56,178              
  Long-term income taxes payable     59,135       67,041              
  Debt       64,796       89,244              
      Total liabilities     1,194,981       1,245,469              
                           
Mezzanine equity     -       1,512              
Shareholders' equity     2,298,596       2,562,444              
      Total liabilities, convertible common shares and shareholders’ equity   $ 3,493,577     $ 3,809,425              
                           
                           
                           
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands)                    
                           
          Quarter Ended   Six Months Ended    
          July 3,
2022
  July 4,
2021
  July 3,
2022
  July 4,
2021
   
Cash flows from operating activities:                    
  Net income   $ 197,787     $ 328,319     $ 359,715     $ 533,831      
                                       
  Adjustments to reconcile net income to net cash provided by operating activities:                    
    Depreciation     21,957       21,938       44,460       45,848      
    Stock-based compensation     12,228       10,999       25,122       23,231      
    Amortization     4,862       9,521       10,095       19,343      
    Provision for excess and obsolete inventory     5,105       798       6,695       3,625      
    Deferred taxes     (34,885 )     257       (23,597 )     (800 )    
    Losses (gains) on investments     6,972       (2,159 )     8,973       (4,650 )    
    Retirement plans actuarial gains     -       (627 )     -       (627 )    
    Contingent consideration fair value adjustment     -       -       -       (7,227 )    
    Loss on convertible debt conversions     -       1,175       -       5,244      
    Other     345       (1 )     522       199      
                           
    Changes in operating assets and liabilities                  
      Accounts receivable     (146,592 )     (285,186 )     (146,384 )     (372,698 )    
      Inventories     (37,202 )     56,320       (46,682 )     19,908      
      Prepayments and other assets     (25,597 )     (31,285 )     (99,902 )     (117,416 )    
      Accounts payable and other liabilities     85,922       97,361       (38,460 )     86,790      
      Deferred revenue and customer advances     7,416       7,237       14,163       15,189      
      Retirement plans contributions     (1,289 )     (814 )     (2,618 )     (2,739 )    
      Income taxes     18,426       (7,569 )     10,815       (2,628 )    
Net cash provided by operating activities     115,455       206,284       122,917       244,423      
                           
Cash flows from investing activities:                    
  Purchases of property, plant and equipment     (45,744 )     (34,707 )     (89,743 )     (73,957 )    
  Purchases of marketable securities     (81,904 )     (186,482 )     (247,881 )     (398,086 )    
  Proceeds from maturities of marketable securities     42,970       265,985       139,652       460,213      
  Proceeds from sales of marketable securities     113,061       54,819       143,642       116,112      
  Purchase of investment     -       (12,000 )     -       (12,000 )    
Net cash provided by (used for) investing activities     28,383       87,615       (54,330 )     92,282      
                           
Cash flows from financing activities:                    
  Issuance of common stock under stock purchase and stock option plans     61       15,437       16,536       32,581      
  Repurchase of common stock     (331,334 )     (151,396 )     (532,799 )     (196,584 )    
  Dividend payments     (17,547 )     (16,604 )     (35,442 )     (33,271 )    
  Payments of convertible debt principal     (21,598 )     (15,553 )     (42,292 )     (66,828 )    
  Payments related to net settlement of employee stock compensation awards     (1,732 )     (1,119 )     (32,780 )     (31,794 )    
Net cash used for financing activities     (372,150 )     (169,235 )     (626,777 )     (295,896 )    
                           
Effects of exchange rate changes on cash and cash equivalents     5,732       (1,372 )     8,014       (489 )    
Decrease (increase) in cash and cash equivalents -   (222,580 )     123,292       (550,176 )     40,320      
Cash and cash equivalents at beginning of period     794,603       831,149       1,122,199       914,121      
Cash and cash equivalents at end of period   $ 572,023     $ 954,441     $ 572,023     $ 954,441      
                           




© 2024 Internet Business Systems, Inc.
670 Aberdeen Way, Milpitas, CA 95035
+1 (408) 882-6554 — Contact Us
ShareCG™ is a trademark of Internet Business Systems, Inc.

Report a Bug Report Abuse Make a Suggestion About Privacy Policy Contact Us User Agreement Advertise